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Dear readers,
A few days ago I was updating my 
CV and I scrolled up the list of publi-
cations, back to my first papers in the
90s. Reading titles and authors of
those early articles I realized how
much my scientific interests have
changed throughout more than 20 years of career. I started as
a synthetic organic chemist, which I still am of course, with
a keen interest in synthetic methodology. I remember the
excitement of finding an unexpected reaction outcome or a
stereoselective process, the time spent wondering how my
substrates would react under different reaction conditions,
how avidly I used to check TLCs scrutinizing the formation
of new spots, looking forward to quenching the reaction and
rushing through a flash chromatography for isolating the
new product and finally run down to the NMR! Developing
new synthetic methodology and synthesizing new molecules
was all I was interested in: I spent all of my time reading
organic chemistry journals, lost in chemical structures and
amazing new reactions or new uses of old ones. But lots of
things have changed and my interests have evolved in line
with my career. First and foremost I don’t have time for
working in the lab anymore, which I am afraid is a necessary
evil. Besides that, I am now much more interested in bio-
medical applications of organic synthesis rather than in the
methodology itself. I have the fortune to work in a biomedi -
cal research institute, where only very few chemists are 
present and our role is to use organic chemistry for finding
solutions to biomedical scientific problems, spanning from
basic biology to applied medicine, from molecular imaging
to drug discovery. That’s what gives me excitement today,
after more than 20 years of career! I am still very proud to
be a chemist and I still believe that chemistry is the central
science, but today the magic of chemistry for me is when my
molecules are successfully used by my colleagues and I
spend all of my time designing applications rather than syn-
thetic methodology. We still have to synthesize our com-
pounds, of course, and for that we try to go as straight and
efficiently as possible to the target without bothering too
much about the methodology aspect. Is this evolution? My
answer is a yes, although I believe that there is absolutely
nothing wrong with sticking to the same scientific interest
and research orientation throughout an entire career, and I
know many colleagues who did just that. Perhaps that’s just
a bit bizarre, taking into account how many stimuli a scien-
tists receives from colleagues, environment and society, not
to mention the funding bodies... So how is it possible not to
be lured by curiosity to different research topics or areas?
That’s what happened to me, and also to many of you, I
guess. On a slightly different note, I have absolutely no
doubts that you will be lured by this new issue of Synform,
because it’s once again packed full of great and exciting
chemistry! We start with a new bioorthogonal process (very
exciting!!!) developed by A. Unciti-Broceta (Scotland, UK),
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and we continue with a novel method for achieving the
cleavage of aromatic C–N bonds reported by 
N. Chatani (Japan). The third SynSTory covers a new
method for using isatine as N-nucleophile in aza-Michael
reactions developed by T. Kanger (Estonia). Finally, the
Young Career Focus on A. Orellana (Canada), an up-
and-coming young organic chemist interested in total
synthesis and new synthetic methodology.
Enjoy your reading!
Editor of Synform
matteo Zanda Do
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Chemotherapy is most effective at killing cells that divide
rapidly, which is one of the principal features of cancer cells.
However, non-cancerous cells are also heavily affected by the
chemotherapeutic treatment. As a result, antineoplastic drugs
are limited by lack of selectivity. To mitigate unwanted side
effects, many efforts have been made on the design of cancer-
specific strategies such as prodrugs, which are inactive pre-
cursors of cytotoxic agents that are biochemically converted
into their active forms in a specific biological setting. As an
unprecedented prodrug approach, the Edinburgh Cancer
Discovery Unit (University of Edinburgh, Scotland, UK) is
investigating the application of solid metals as implantable
activating devices to modulate the cytotoxic activity of anti-
neoplastic drugs in a spatially controlled manner.
The novel approach, so-called bioorthogonally activated
chemotherapy, is based on the use of palladium, a benign
metal able to catalyze various chemical reactions in biocom-
patible environments (Nat. Chem. 2011, 3, 239; Synform
2011, 06, A48; Nat. Protocols 2012, 7, 1207; Chem. Soc.
Rev. 2013, 42, 7943). “While soluble palladium species such
as Pd2+ complexes exhibit inherent cytotoxic properties,
metallic palladium (Pd0) is biocompatible (e.g., it is employed
in dental restoration) and we have now shown that it is ca t -
al y tically active both in vitro (cell culture) and in vivo
(zebrafish),” said Dr. Unciti-Broceta, who led the research
program that resulted in this Nat. Commun. article.
As opposed to classical prodrugs, whose activation process
relies on metabolic pathways, an efficient palladium-activated
prodrug therapy ought to be entirely dependent on the pres-
ence of this metal and the prodrug should remain intact in dis-
tant tissues and organs. “The principal challenges to over-
come were to make the prodrug metabolically stable (= bio -
orthogonal) while at the same time sensitive to palladium
catalysis,” confirmed Dr. Unciti-Broceta. 5-Fluorouracil
(5FU), a potent antimetabolite drug, whose clinical use has
been limited by a narrow therapeutic index, was used to
develop such a prodrug. According to the authors, 5FU was
modified at its N1 position (i) because of its relatively low pKa
value due to the heterocycle’s lactam/lactim tautomery, which
was expected to promote its properties as a leaving group, and
(ii) due to its relevance in the drug’s mode of action (see
Figure, A). “We hypothesized that the alkylation of the N1
position of 5FU would both suppress the drug’s cytotoxic
properties and make the resulting prodrug become resistant to
enzymatic cleavage,” said Dr. Unciti-Broceta.
“We have found that inactive prodrugs can be generated by
masking the N1 position of 5FU with allyl, propargyl and ben-
zyl groups. Our results show, however, that only the propargyl
derivative displays high sensitivity to palladium in biocom-
patible conditions and enables the bioorthogonal generation
of 5FU by heterogeneous palladium catalysis in cancer cell
culture (see Figure, B),” said Jason Weiss, currently a final-
year PhD student in the Unciti-Broceta group. The authors
noted that the oxidative cleavage of the propargyl group gen-
erates 1-hydroxyacetone, a harmless natural compound, as
reaction byproduct, making the reaction optimal to activate
any kind of prodrug in vivo (not only cytotoxic ones).
“This is the first example showing that the pharmacologi-
cal activity of a clinically approved antineoplastic drug can be
locally activated by means of an internal self-renewable con-
trol element rather than an external radiation source (such as
in photodynamic therapy),” said Dr. Neil Carragher, a group
leader of the Edinburgh Cancer Research UK Centre and
expert in phenotypic screening. According to Dr. Carragher,
this novel approach would allow for a reduction in adverse
side effects of current chemotherapeutic regimes. The pro-
posed strategy would be optimal to treat advanced cancers
that cannot be resected by surgery, since it would allow local
treatment with increased dosing. Once the tumor has shrunk
to a resectable size, the surgeon could remove the tumor along
with the palladium implants. Dr. Unciti-Broceta concluded:
“The next steps of the project are to validate this approach in
a mouse cancer model and to expand the chemistry to other
pharmaceuticals.”  
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figure  (A) 5FU and its conjugate bases (top) and intracellular biofunctionalization of 5FU to generate cytotoxic metabolites (bottom). 
(B) In situ transformation of an inert drug precursor into a bioactive material (5FU) by the mediation of an extracellular biocompatible catalyst 
in cell culture.
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About the authors
Jason Weiss was born in Ottawa (Canada) in 1985. He com-
pleted his Honors Bachelor of Science degree in Biotechnology
at Carleton University (Ottawa). Afterwards, he worked for
Nordion in the radiopharmaceutical production division as a
drug production technician synthesizing medical isotopes. After
two years, he went back to school to the University of Edin -
burgh (UK) where he obtained his MSc in Biomedical Sciences.
He is currently pursuing his PhD in Molecular Medicine (Edin -
burgh Cancer Research UK Centre, University of Edinburgh)
under the supervision of Asier Unciti-Broceta working on the
development of antineoplastic prodrugs sensitive to palladium
as a novel spatially controlled anticancer chemotherapy.
Neil Carragher was born in Uphall, Scotland (UK) in 1970. He
studied ‘Cell and Immunobiology’ at the University of Aberdeen
(UK) prior to accepting a position at the Yamanouchi Research
Institute, Oxford (UK) where he obtained his PhD in 1996. He
held consecutive postdoctoral positions within the Department
of Pathology, University of Washington, Seattle (USA) and at the
Beatson Institute for Cancer Research, Glasgow (UK). In 2004
Neil returned to the pharmaceutical industry as Principal Scien -
tist with the Advanced Science and Technology Labora tory at
AstraZeneca where he pioneered early multiparametric high-
content phenotypic screening approaches. In 2010 he returned
to academia and took up the post of Principal Investigator at
the University of Edinburgh where he leads a research group
and is currently co-director of the Edinburgh Cancer Discovery
Unit. Current research interests include advancing high-content
analysis, phenotypic screening, reverse-phase protein array
technology and cancer drug discovery.
Asier Unciti-Broceta was born in La Linea (Spain) in 1976.
After studying ‘Pharmaceutical Sciences’ at the University of
Granada (Spain), he completed his PhD in Medicinal Chemistry
under the supervision of Professor A. Espinosa and sponsored
by the Ramón Areces Foundation in 2004. He then moved to
the University of Edinburgh (UK) to join the group of Professor
M. Bradley (School of Chemistry) as a postdoctoral fellow.
Following a Scottish Enterprise Proof of Concept Award in
2008, which resulted in the foundation of the spin-out company
Deliverics Ltd, in 2010 he became the first chemistry group 
leader of the Edinburgh Cancer Research UK Centre (MRC
Institute of Genetics and Molecular Medicine, University of
Edin burgh). His research interests lie on the interface of medi -
cinal chemistry and chemical biology, with particular emphasis
on the design and development of innovative anticancer pro-
drugs and kinase inhibitors. Among his awards, highlights 
include being the recipient of the Nexxus Young Life Scientist
Award of 2010 and the RSC Young Industrialist Award of 2012.
In 2013 he was appointed co-director of the Edinburgh Cancer
Discovery Unit and member of the RSE Young Academy of
Scotland.
From left to right: Dr. A. Unciti-Broceta, J. Weiss, Dr. N. Carragher
(other authors: J. Dawson, K. Macleod, C. Fraser, L. Patton, 
M. Bradley)
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Although substantial progress has been made in the devel-
opment of catalytic C(aryl)–N bond-formation reactions for
the construction of aryl amine derivatives, reports pertaining
to the reverse process, namely the catalytic cleavage of
C(aryl)–N bonds, remain scarce. C(aryl)–N bond cleavage of
aniline derivatives normally requires the use of highly reac-
tive cationic intermediates, such as diazonium and ammonium
salts, in which the elimination of electronically neutral dini-
trogen and amine moieties facilitates the C–N bond-cleavage
process. A notable exception to this is the ruthenium-cat-
alyzed C–N bond activation of electronically neutral aniline
derivatives, although applicable substrates are limited to com-
pounds that contain ortho-directing groups. Recently, the
group of Professor Naoto Chatani and Associate Professor
Mamoru Tobisu at Osaka University (Japan) reported on a
catalytic method for cleavage of C(aryl)–N bonds of electron-
ically neutral, simple aryl amine derivatives, including amides
and carbamates. The process involves the nickel-catalyzed
conversion of inert C(aryl)–N bonds into C(aryl)–H and
C(aryl)–B bonds.
Professor Chatani said: “Our research group has focused
on the development of new catalytic methods that can be used
for the direct transformation of strong s-bonds, including
C–H, C–C and C–O bonds. In this context, we previously
reported a series of nickel-catalyzed cross-coupling reactions
using anisole derivatives as aryl halide surrogates (for a
review, see: Top. Organomet. Chem. 2013, 44, 35). We
wondered whether the low-valent nickel species could be used
for the transformation of even stronger s-bonds.” After select-
ing C(aryl)–N bonds as the target for cleavage by nickel
Synform, 2014/07
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catalysis, the Osaka-based researchers examined a series of
reagents, ligands and reaction conditions. “The first promis-
ing result was obtained just after Keisuke Nakamura joined
the group as an undergraduate researcher,” revealed Associate
Professor Tobisu. “He examined the nickel-catalyzed reaction
of 1-(naphthalen-2-yl)pyrrolidin-2-one with hydrosilane and
found that naphthalene, a C–N bond-cleavage product, was
formed in 7% yield. He dedicated his master’s degree studies
to further developing this intriguing C–N bond-cleavage
reaction.” After considerable study, the reductive cleavage of
C–N bonds was revealed to proceed in synthetically useful
yield when hydroborane was used as the reducing agent.
Professor Chatani concluded: “What excited us even more
was that substitution of an amide group by a boryl group was
also possible when a diboron reagent was used. Although the
mechanism responsible for this new C–N activation process
is unclear at present, we conclude that the C(aryl)–N bond
cleavage reaction can now be considered to be a viable
methodology for enabling a nonconventional synthetic strate-
gy.”
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About the authors
Mamoru Tobisu received his PhD from Osaka University
(Japan) in 2001 under the direction of Professor Shinji Murai.
During the course of his PhD studies, he also worked with
Professor Gregory C. Fu at the Massachusetts Institute of
Technology (USA) as a visiting scientist (1999). Following a
period of employment with the Takeda Pharmaceutical Com -
pany, Japan (2001–2005), he began his academic career at
Osaka University in 2005 as an Assistant Professor. He then
moved to the Frontier Research Base for Global Young
Researchers at Osaka University as a lecturer in 2006 and
was appointed as an Associate Professor at the Center for
Atomic and Molecular Technologies at Osaka University in
2011.
From left to right: Prof. M. Tobisu, K. Nakamura, Prof. N. Chatani
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Keisuke Nakamura graduated from Osaka University (Japan)
in 2011 and obtained his MSc from the same university in
2013. He is currently pursuing his PhD under the supervision 
of Professors Chatani and Tobisu at Osaka University.
Naoto Chatani received his PhD in 1984 under the guidance
of Professors Noboru Sonoda and Shinji Murai. In 1984 he 
joined the Institute of Scientific and Industrial Research at
Osaka University (Japan) and was involved in research in the
laboratory of Professor Terukiyo Hanafusa. After postdoctoral
studies (1988–1989 under Professor Scott E. Denmark at the
University of Illinois, Urbana-Champaign, USA), he moved back
to Osaka University and was promoted to Associate Professor
in 1992 and to Full Professor in 2003.
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Isatin (1) is a versatile compound whose derivatives have a
part to play in different branches of chemistry, varying from
dyes to efficient antibacterial agents. Its chemistry has been
studied thoroughly and electrophilic substitution in an aro-
matic ring, dipolar cycloaddition and especially the nucle-
ophilic addition to the C3 carbonyl function of isatin are well-
described reactions (for references, see the Org. Lett. article).
Synform, 2014/07
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Scheme  The new aza-Michael reaction and its scope
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The multifunctionality of isatin makes it an attractive tar-
get for various cascade reactions with other multifunctional
compounds, a topic that the group of Professor Tõnis Kanger
at the Tallinn University of Technology (Estonia) has been
working on for some time. “Our first idea was to contribute to
the organocatalytic asymmetric synthesis of N-heterocyclic
spiro-oxindoles,” said Professor Kanger. “We planned to
derivatize isatin to imine 2 and perform a Mannich–aza-
Michael cascade reaction using enolizable 1,4-unsaturated
dicarbonyl compounds. However, no one could predict that
instead of this contribution we would get a new topic to study
and that a single HPLC analysis done ‘out of interest’ would,
over time, lead to a new method for using isatin as a nucle-
ophile in aza-Michael reactions.” This new methodology rep-
resents an efficient and straightforward approach to the syn-
thesis of highly enantiomerically enriched N-substituted
isatins and also opens the possibility of achieving new cas-
cade reactions. According to Professor Kanger, in fact, this is
the first example of remote activation of nucleophilicity in an
organocatalytic reaction.
Professor Kanger remarked: “While isatin itself efficiently
reacts in this aza-Michael reaction, its simple derivatization is
the key step for achieving high enantioselectivity and at the
same time blocking possible side reactions.” He concluded:
“Moreover, additional studies showed that you can’t simply
derivatize isatin with just any primary amine for this positive
effect to take place: aniline provides the best combination of
high yields and excellent enantiocontrol. We are still working
on understanding the mechanism by which the imine aromatic
ring makes the reaction efficient by combining experiments
with NMR studies and theoretical calculations and expanding
the range of suitable Michael acceptors.”
Synform, 2014/07
Published online: 16.06.2014, DOI: 10.1055/s-0033-1340191
2 0 1 4  © T H I E M E   S T U T T G A RT  ·  N E W   Y O R K
SynSTorIES A97
About the authors
Tõnis Kanger received his BSc 
in 1982 from Tartu University
(Estonia) and PhD in 1990 from the
Estonian Academy of Sciences.
After postdoctoral studies at the
Pierre et Marie Curie University
(France), under the supervision of
Professor Alexandre Alexakis, he
returned to Estonia, where he is
currently professor at Tallinn
University of Technology. His
research interests are focused on
metho dology of organic synthesis, chemical asymmetric
synthesis and organocatalysis.
Sergei Žari was born in Tallinn (Estonia) in 1987. He started
his studies at Tallinn University of Technology in 2005 and
joined Professor Tõnis Kanger’s group during his first year of
bachelor’s studies. He received his BSc in chemistry and
biotechnology in 2009 followed by an MSc in 2011. He is
currently a third-year PhD student under the supervision of
Professor Tõnis Kanger. His main research interest is the
application of asymmetric organocatalysis for the synthesis
of biologically active chiral compounds.
Prof. T. Kanger
S. Žari
matteo Zanda
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Background and Purpose. Synform will from time
to time meet young up-and-coming researchers who are per-
forming exceptionally well in the arena of organic chemistry
and related fields of research, in order to introduce them to the
readership. This SynSTory with a Young Career Focus pres-
ents Dr. Arturo Orellana, York University, Canada.
InTErVIEW
Synform What is the focus of your current research
activity? 
Dr. Arturo Orellana For the last few years we have been
exploring the palladium-catalyzed chemistry of tertiary alco-
hols. We have focused most of our work on strained tertiary
alcohols because they display very unique reactivity. Many
of these substrates in fact undergo base- or acid-catalyzed
reactions leading to ring-opened products; using palladium
catalysis we have been able to control their reactivity such
that they can participate in carbon–carbon bond-forming
reactions.
Synform When did you get interested in synthesis?
Dr. Arturo Orellana I was first exposed to organic chem-
istry in a large undergraduate class taught by Professor Tony
Durst at the University of Ottawa. This is the kind of organic
chemistry class that all science majors take and that is 
populated by many students with medical school ambitions.
Before actually sitting in class, I was a bit intimidated by the
subject’s reputation, but Professor Durst did an amazing job
at teaching this course and it all made perfect sense, it was
like a new language with its own logical rules. A year or so
later I became aware of natural product synthesis as a dis -
cipline. The idea of building complex molecular structures
really appealed to me and is what I pursued with Professor
Alex Fallis as an undergraduate student, and with the late
Professor Ed Piers (at the University of British Columbia)
for graduate school.
Synform What do you think about the modern role 
and prospects of organic synthesis?
Dr. Arturo Orellana I think organic synthesis is as impor-
tant as ever, there will always be a need to build molecular
structures on demand. That is not to say that the same kind
of research that was being carried out 10 or 20 years ago is
held in the same high regard now as it was then. 
Young Career Focus: Dr. Arturo Orellana 
(York University, Canada)
BIoGrAPHICAL SKETCH
Arturo (Art) Orellana was born 
in El Salvador and emigrated to
Ottawa (Canada) in 1986. He
obtained a B.Sc. (Honours) degree
from the University of Ottawa in
1997, where he conducted under-
graduate research with Professor
Alex Fallis. He carried out gradua-
te studies at the University of
British Columbia (Canada) with the
late Professor Edward Piers on the
synthesis of terpene natural pro-
ducts. He was a Chateaubriand post-doctoral fellow under
Professor Andrew E. Greene at the Université Joseph
Fourier in Grenoble (France), and also conducted post-doc-
toral research with Professor Tomislav Rovis at Colorado
State University (USA). He began his independent career at
York University (Canada) in 2007. In 2012, he received the
Boehringer-Ingelheim Young Investigator Award for Organic
Chemistry in Canada.
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Specifically, total synthesis as an end in itself, using known
technology, is not going to add very much to the field. That
said, there is some excellent research in synthesis being done
today that is extremely impressive and inspiring. Generally,
this research tackles the challenges of molecular complexity
and synthetic efficiency (step and redox economy, etc.) head
on, and will likely benefit the field the most. I expect that
there is still a lot of work to be done before we can confi-
dently say that we can make any molecule efficiently and 
on scale. 
Synform Your research group is active in the areas of
total synthesis and development of new synthetic metho -
dology. Could you tell us more about your research and its
aims?
Dr. Arturo Orellana We have been using tertiary alcohols
in palladium-catalyzed reactions, where they can be used as
surrogates for oxidative addition partners or organometallic
reagents. The attractive aspect of this kind of cross-coupling
reaction is that a new functional group (a ketone) is revealed
as a new carbon–carbon bond is formed (see Scheme). 
This is in contrast to most cross-coupling reactions, which
generally result in a net reduction of functional group con-
tent in the product. Obviously, this has important synthetic
implications. In some instances, the new ketone can parti -
cipate in downstream reactions in the same pot, leading to
some interesting and efficient synthetic strategies. There are
a number of researchers working on very similar themes
with related substrate classes, so we have been careful in
terms of substrate choice and focused mostly on cyclo-
propanols and benzocyclobutenols.
Synform What is your most important scientific
achieve ment to date and why?
Dr. Arturo Orellana I think we have made some valuable
contributions to synthetic methodology that could prove very
useful in the right context, but I always try to be careful not
to overstate their importance. That said, I think that extend-
ing the cyclopropanol-homoenolate idea (first developed by
Kuwajima) to a broader scope will prove valuable (Professor
Patrick Walsh has also made important recent contributions
in this area). We were also the first to control the ring-open-
ing reactions of benzocyclobutenols, and since our first
report other researchers have begun to explore this substrate
class as well.
Synform, 2014/07
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